RE:RE:RE:RE:RE:RE:RE:For anyone new hereAgreed. The delay in D to C cost them about 6 months in Aristotle revenues while they pivoted to the Care deal. But that is being corrected and once it starts to take off it will gain traction and incremental growth.
Meanwhile the Care Oncology business is still ongoing and was growing at a rate of 70% according to the CEO.
-CoVid revenue
-Care Oncology revenues and
-now the roll out of Direct to Consumer for Aristotle at the 2 lab locations in California and Richmond.
-A hub and spoke strategy (ie more location sites)
-Partnerships with multiple blood drawing companies (Quest Diagnostic, Phlebfinders, Ichor Blood, and others).
-Employers and large health care to come
Mykndrsn wrote: Their continuing obvious interest contradicts their narrative. Szls revenues and profits are increasing exponentially which is hard for even the dimest bulbs to ignore.